PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “AMPULES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources

Thermal degradation of PCDD/F in municipal solid waste ashes in sealed glass ampules.

Due to their high concentrations of toxic organic compounds such as polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/F), metals, and water-soluble salts, fly ashes are classified as hazardous waste in the European Union and are required to be deposited in controlled landfills. We have shown here that the tetra- to octachlorinated PCDD/F in fly ash can be degraded by thermal treatment. The temperature needed for total degradation of PCDD/F depends on the composition of the fly ash. Its concentrations of unburned carbon and alkaline compounds were found to be important in this respect. Experimental design was used to investigate the effects of varying the temperature, residence time, and atmosphere on the degradation of PCDD/F in three different types of fly ash. The results showed that the three ashes clearly showed different degradation potentials for PCDD/F during thermal treatment. The concentrations of unburned carbon, alkaline species such as CaO and Na2O, and metals such as copper and iron strongly influenced the degradation of PCDD/F. However, the different combinations of pH and amounts of native PCDD/F, unburned carbon, metals (Cu, Fe, Sn and Na), and sulfur in the ashes made it difficult or even impossible to conclude that any single parameter was responsible for the degradation of PCDD/F in these thermal treatment experiments. The decreases observed in all of the experiments are due to dechlorination and/or destruction of PCDD/F: depending on the temperature and ash composition, either of these processes may be the more important.

Air↗

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group.

According to international guidelines, the level and adjustment of antiinflammatory treatment for asthma are based solely on symptoms and lung function. We investigated whether a treatment strategy aimed at reducing airway hyperresponsiveness (AHR strategy) in addition to the recommendations in the existing guidelines (reference strategy) led to: (1) more effective control of asthma; and (2) greater improvement of chronic airways inflammation. To accomplish this, we conducted a randomized, prospective, parallel trial involving 75 adults with mild to moderate asthma who visited a clinic every 3 mo for 2 yr. At each visit, FEV1 and AHR to methacholine were assessed, and subjects kept diaries of symptoms, beta2-agonist use, and peak expiratory flow (PEF). Medication with corticosteroids (four levels) was adjusted according to a stepwise approach (reference strategy), to which four severity classes of AHR were added (AHR strategy). At entry and after 2 yr, bronchial biopsies were obtained by fiberoptic bronchoscopy. Patients treated according to the AHR strategy had a 1.8-fold lower rate of mild exacerbations than did patients in the reference strategy group (0. 23 and 0.43 exacerbation/yr/patient, respectively). FEV1 also improved to a significantly greater extent in the AHR strategy group (p </= 0.05). In bronchial biopsies this was accompanied by a greater reduction in thickness of the subepithelial reticular layer in the AHR strategy group than in the reference strategy group (mean difference [95% confidence interval (CI): 1.7 micrometers (0.2 to 3.1) micrometers]). The changes in AHR in both strategy groups were correlated with eosinophil counts in the biopsies (r = -0.48, p = 0.003). We conclude that reducing AHR in conjunction with optimizing symptoms and lung function leads to more effective control of asthma while alleviating chronic airways inflammation. This implies a role for the monitoring of AHR or other surrogate markers of inflammation in the long-term management of asthma.

Administration, Inhalation↗

Glass ampules.

Explore the source record for details and available documents.

Anesthesiology↗